Category: 16506-27-7

Spectroscopic, quantum mechanical, electronic excitation properties (Ethanol solvent), DFT investigations and molecular docking analysis of an anti-cancer drug Bendamustine was written by Ramana, P. Venkata;Sundius, Tom;Muthu, S.;Mouli, K. Chandra;Krishna, Y. Rama;Prasad, K. Venkata;Devi, R. Niranjana;Irfan, Ahmad;Santhamma, C.. And the article was included in Journal of Molecular Structure in 2022.HPLC of Formula: 16506-27-7 The following contents are mentioned in the article:

In this investigation, optimization geometry of the mol., FT-IR, FT-Raman, and UV-Vis spectra, vibrational frequencies, assigning of suitable vibrational modes of Bendamustine (an anti-cancer drug) were summarised on the grounds of distribution of potential energy. Spectroscopic investigations are attempted by employing DFT/B3LYP with 6-311++G (d, p) level. The output of the computations was implemented to model the spectra of the Bendamustine, which agrees well with the recorded spectra. The TDFT had been utilized to compute the strengths of oscillators. To ascertain the transfer of charge inside the mol. HOMO and LUMO analytics have been utilized. The NBO investigation has been employed to verify the stability of the mol. by observing internal charge transfer, hyperconjugation, and energy of stabilization. Mol. electrostatic potential and Mulliken’s charges were thoroughly studied by using DFT methods. The NLO characteristics of the title drug mol. were investigated with B3LYP and HF basis functionals. The reactive sites and reactivity of the title drug mol. have been extensively studied with help of condensed Fukui functions and global descriptors. The mol. docking investigations of the title drug mol. were executed with the DNA binding protein of Cellular Tumor Antigen P53. This study involved multiple reactions and reactants, such as 4-(5-(Bis(2-chloroethyl)amino)-1-methyl-1H-benzo[d]imidazol-2-yl)butanoic acid (cas: 16506-27-7HPLC of Formula: 16506-27-7).

4-(5-(Bis(2-chloroethyl)amino)-1-methyl-1H-benzo[d]imidazol-2-yl)butanoic acid (cas: 16506-27-7) belongs to imidazole derivatives. Imidazole is the basic core of some natural products such as histidine, purine, histamine and DNA based structures, etc. Among the different heterocyclic compounds, imidazole is better known due to its broad range of chemical and biological properties. Imidazole based anticancer drug find applications in cancer chemotherapy. It is used as buffer component for purification of the histidine tagged recombinant proteins in immobilized metal-affinity chromatography (IMAC).HPLC of Formula: 16506-27-7

Referemce:
Imidazole – Wikipedia,
Imidazole | C3H4N2 – PubChem

Reappraisal of the prognostic value of Epstein-Barr virus status in monomorphic post-transplantation lymphoproliferative disorders-diffuse large B-cell lymphoma was written by Kim, Jwa Hoon;Cho, Hyungwoo;Sung, Heungsup;Jung, Ah Ra;Lee, Yoon Sei;Lee, Sang-wook;Ryu, Jin-Sook;Chae, Eun Jin;Kim, Kyoung Won;Huh, Jooryung;Park, Chan-Sik;Yoon, Dok Hyun;Suh, Cheolwon. And the article was included in Scientific Reports in 2021.Category: imidazoles-derivatives The following contents are mentioned in the article:

Abstract: The role of the Epstein-Barr virus (EBV) status in the blood for predicting survival in post-transplantation lymphoproliferative disorders-diffuse large B-cell lymphoma (PTLD-DLBCL) is unknown. We evaluated the prognostic values of pre-treatment EBV-encoded small RNA (EBER) detected with in situ hybridization in tissues and EBV DNA in the whole blood (WB) and plasma in 58 patients with monomorphic PTLD-DLBCL after solid organ transplantation. There were no significant differences in the rates of overall response, complete response, and survival according to EBER EBV and WB EBV status. In contrast, patients with pos. plasma EBV DNA had significantly lower rates of overall response (60.0% vs. 94.4%, P = 0.043) and complete response (40.0% vs. 88.9%, P = 0.019) as well as worse progression-free survival (PFS) (P = 0.035) and overall survival (OS) (P = 0.039) compared with patients with neg. plasma EBV DNA. In multivariate anal., plasma EBV DNA positivity was a significantly unfavorable prognostic factor for PFS [hazard ratio (HR) 4.92, 95% confidence interval (CI) 1.22-19.86, P = 0.025] and OS (HR 4.48, 95% CI 1.14-17.63, P = 0.032). Despite small number of 6 patients with plasma EBV positivity, plasma EBV DNA positivity might be more prognostic for survival than EBER or WB EBV DNA positivity in patients with monomorphic PTLD-DLBCL. This study involved multiple reactions and reactants, such as 4-(5-(Bis(2-chloroethyl)amino)-1-methyl-1H-benzo[d]imidazol-2-yl)butanoic acid (cas: 16506-27-7Category: imidazoles-derivatives).

4-(5-(Bis(2-chloroethyl)amino)-1-methyl-1H-benzo[d]imidazol-2-yl)butanoic acid (cas: 16506-27-7) belongs to imidazole derivatives. The solubility of imidazoles in ethers is lower than that in alcohols and decreases with increasing chain length of the ethers . In contrast, the solubility of benzimidazoles in alcohols (C3鈥揅6) is higher than in water and generally decreases with a Imidazole derivatives have antibacterial, antifungal and anticancer functionality. It interacts with DNA and also binds to protein and stops cell division.Category: imidazoles-derivatives

Referemce:
Imidazole – Wikipedia,
Imidazole | C3H4N2 – PubChem

JAK3 mutations and mitochondrial apoptosis resistance in T-cell acute lymphoblastic leukemia was written by Bodaar, Kimberly;Yamagata, Natsuko;Barthe, Anais;Landrigan, Jack;Chonghaile, Triona Ni;Burns, Melissa;Stevenson, Kristen E.;Devidas, Meenakshi;Loh, Mignon L.;Hunger, Stephen P.;Wood, Brent;Silverman, Lewis B.;Teachey, David T.;Meijerink, Jules P.;Letai, Anthony;Gutierrez, Alejandro. And the article was included in Leukemia in 2022.Reference of 16506-27-7 The following contents are mentioned in the article:

Resistance to mitochondrial apoptosis predicts inferior treatment outcomes in patients with diverse tumor types, including T-cell acute lymphoblastic leukemia (T-ALL). However, the genetic basis for variability in this mitochondrial apoptotic phenotype is poorly understood, preventing its rational therapeutic targeting. Using BH3 profiling and exon sequencing anal. of childhood T-ALL clin. specimens, we found that mitochondrial apoptosis resistance was most strongly associated with activating mutations of JAK3. Mutant JAK3 directly repressed apoptosis in leukemia cells, because its inhibition with mechanistically distinct pharmacol. inhibitors resulted in reversal of mitochondrial apoptotic blockade. Inhibition of JAK3 led to loss of MEK, ERK and BCL2 phosphorylation, and BH3 profiling revealed that JAK3-mutant primary T-ALL patient samples were characterized by a dependence on BCL2. Treatment of JAK3-mutant T-ALL cells with the JAK3 inhibitor tofacitinib in combination with a spectrum of conventional chemotherapeutics revealed synergy with glucocorticoids, in vitro and in vivo. These findings thus provide key insights into the mol. genetics of mitochondrial apoptosis resistance in childhood T-ALL, and a compelling rationale for a clin. trial of JAK3 inhibitors in combination with glucocorticoids for patients with JAK3-mutant T-ALL. This study involved multiple reactions and reactants, such as 4-(5-(Bis(2-chloroethyl)amino)-1-methyl-1H-benzo[d]imidazol-2-yl)butanoic acid (cas: 16506-27-7Reference of 16506-27-7).

4-(5-(Bis(2-chloroethyl)amino)-1-methyl-1H-benzo[d]imidazol-2-yl)butanoic acid (cas: 16506-27-7) belongs to imidazole derivatives. Many natural products, especially alkaloids, contain the imidazole ring. These imidazoles share the 1,3-C3N2 ring but feature varied substituents. Imidazole is incorporated into many important biological compounds. The most pervasive is the amino acid histidine, which has an imidazole side-chain. Histidine is present in many proteins and enzymes, e.g. by binding metal cofactors, as seen in hemoglobin.Reference of 16506-27-7

Referemce:
Imidazole – Wikipedia,
Imidazole | C3H4N2 – PubChem

Validated liquid chromatography-tandem mass spectrometry method for simultaneous quantitation of bendamustine and copanlisib in mouse plasma: Application to a pharmacokinetic study in mice was written by Tripathy, Harsha K.;Manju, S. V. Nair;Bestha, Rama Murthy;Kiran, Vinay;Dittakavi, Sreekanth;Mullangi, Ramesh. And the article was included in Biomedical Chromatography in 2022.Reference of 16506-27-7 The following contents are mentioned in the article:

In this study, we report the development and validation of an LC-tandem mass spectrometry method for the simultaneous quantitation of bendamustine and copanlisib in mouse plasma as per the US FDA regulatory guidelines. The sample processing involves extraction of bendamustine and copanlisib along with internal standard (IS; warfarin) from 50渭L mouse plasma using a liquid-liquid extraction method. The chromatog. separation of bendamustine, copanlisib and the IS was achieved on an Atlantis dC18 column using an isocratic mobile phase (5 mM ammonium acetate:methanol, 20:80 volume/volume). Bendamustine, copanlisib and the IS eluted at 0.88, 1.39 and 0.74 min, resp., with a total run time of 2.5 min. The calibration curve ranged from 3.99-2996 and 4.33-3248 ng/mL for bendamustine and copanlisib, resp. Inter- and intra-day precision and accuracy, stability in processed samples and upon storage, dilution integrity and incurred sample reanal. were investigated for both the analytes. The intra- and inter-day precisions were in the ranges of 2.01%-5.05% and 2.74%-6.13% and 1.98%-7.64 and 8.62%-9.04% for bendamustine and copanlisib, resp. Stability studies showed that both analytes were stable on bench top for 6 h, in auto-sampler for 24 and at -80掳C for 30 days. The validated method was successfully applied to a pharmacokinetic study in mice. This study involved multiple reactions and reactants, such as 4-(5-(Bis(2-chloroethyl)amino)-1-methyl-1H-benzo[d]imidazol-2-yl)butanoic acid (cas: 16506-27-7Reference of 16506-27-7).

4-(5-(Bis(2-chloroethyl)amino)-1-methyl-1H-benzo[d]imidazol-2-yl)butanoic acid (cas: 16506-27-7) belongs to imidazole derivatives. Among the different heterocyclic compounds, imidazole is better known due to its broad range of chemical and biological properties. Imidazole has become an important synthon in the development of new drugs. This ring system is present in important biological building blocks, such as histidine and the related hormone histamine.Reference of 16506-27-7

Referemce:
Imidazole – Wikipedia,
Imidazole | C3H4N2 – PubChem

Identification and verification of m7G modification patterns and characterization of tumor microenvironment infiltration via multi-omics analysis in clear cell renal cell carcinoma was written by Dong, Kai;Gu, Di;Shi, Jiazi;Bao, Yewei;Fu, Zhibin;Fang, Yu;Qu, Le;Zhu, Wentong;Jiang, Aimin;Wang, Linhui. And the article was included in Frontiers in Immunology in 2022.Quality Control of 4-(5-(Bis(2-chloroethyl)amino)-1-methyl-1H-benzo[d]imidazol-2-yl)butanoic acid The following contents are mentioned in the article:

The epigenetic modification of tumorigenesis and progression in neoplasm has been demonstrated in recent studies. Nevertheless, the underlying association of N7- methylguanosine (m⁷ G) regulation with mol. heterogeneity and tumor microenvironment (TME) in clear cell renal cell carcinoma (ccRCC) remains unknown. Author explored the expression profiles and genetic variation features of m⁷ G regulators and identified their correlations with patient outcomes in pan-cancer. Three distinct m⁷ G modification patterns, including MGCS1, MGCS2, and MGCS3, were further determined and systematically characterized via multi-omics data in ccRCC. Compared with the other two subtypes, patients in MGCS3 exhibited a lower clin. stage/grade and better prognosis. MGCS1 showed the lowest enrichment of metabolic activities. MGCS2 was characterized by the suppression of immunity. Author then established and validated a scoring tool named m7Sig, which could predict the prognosis of ccRCC patients. This study revealed that m⁷ G modification played a vital role in the formation of the tumor microenvironment in ccRCC. Evaluating the m⁷ G modification landscape helps us to raise awareness and strengthen the understanding of ccRCC’s characterization and, furthermore, to guide future clin. decision making. This study involved multiple reactions and reactants, such as 4-(5-(Bis(2-chloroethyl)amino)-1-methyl-1H-benzo[d]imidazol-2-yl)butanoic acid (cas: 16506-27-7Quality Control of 4-(5-(Bis(2-chloroethyl)amino)-1-methyl-1H-benzo[d]imidazol-2-yl)butanoic acid).

4-(5-(Bis(2-chloroethyl)amino)-1-methyl-1H-benzo[d]imidazol-2-yl)butanoic acid (cas: 16506-27-7) belongs to imidazole derivatives. Imidazole derivatives generally have good solubility in protic solvents. Simple imidazole derivatives, such as 1H-imidazole, 2-methyl-1H-imidazole, and 1,2-dimethylimidazole, have very high solubility in water. Many drugs contain an imidazole ring, such as certain antifungal drugs, the nitroimidazole series of antibiotics, and the sedative midazolam.Quality Control of 4-(5-(Bis(2-chloroethyl)amino)-1-methyl-1H-benzo[d]imidazol-2-yl)butanoic acid

Referemce:
Imidazole – Wikipedia,
Imidazole | C3H4N2 – PubChem

Frequency and component analysis of contaminants generated in preparation of anticancer agents using closed system drug transfer devices (CSTDs) was written by Sumikawa, Satomi;Yakushijin, Yoshihiro;Aogi, Kenjiro;Yano, Takuya;Hiroki;Hashimoto;Tsukui, Chiyuki;Noguchi, Tadashi;Shiraishi, Taro;Horikawa, Yasuhiro;Yasuoka, Yasuo;Tanaka, Akihiro;Hidaka, Noriaki;Tanaka, Mamoru. And the article was included in Scientific Reports.COA of Formula: C16H21Cl2N3O2 The following contents are mentioned in the article:

Occupational exposure of anticancer agents during their preparation has been recognized as a serious hazard. Closed system drug transfer devices (CSTDs) enable “safe” preparation of agents for medical personnel and ensure a safe hospital environment. However, artificial particles of infusion materials have been reported during CSTD use. Here, the incidence of insoluble fine particles during preparation of anticancer agents using CSTDs was examined Visible insoluble fine particles were found in 465 (9.4%) of 4948 treatment cases at Ehime University Hospital with CSTD use. Contaminants occurred more frequently during preparation of monoclonal antibodies than cytotoxic anticancer agents (19.4% vs. 4.1%, resp., P < 0.01). A similar survey was conducted at nine hospitals to investigate the incidence of insoluble fine particles with or without CSTDs. Insoluble fine particles were detected in 113 (15.4%) of 732 treatment cases during preparation of monoclonal antibodies with CSTD use. In contrast, the occurrence of insoluble fine particles without CSTDs was found in only 3 (0.073%) of 4113 treatment cases. Contamination with CSTDs might cause harmful effects on patients during cancer therapy. We strongly recommend the use of in-line filters combined with infusion routes after CSTD use to avoid contamination-associated adverse events. This study involved multiple reactions and reactants, such as 4-(5-(Bis(2-chloroethyl)amino)-1-methyl-1H-benzo[d]imidazol-2-yl)butanoic acid (cas: 16506-27-7COA of Formula: C16H21Cl2N3O2).

4-(5-(Bis(2-chloroethyl)amino)-1-methyl-1H-benzo[d]imidazol-2-yl)butanoic acid (cas: 16506-27-7) belongs to imidazole derivatives. The solubility of imidazoles in ethers is lower than that in alcohols and decreases with increasing chain length of the ethers . In contrast, the solubility of benzimidazoles in alcohols (C3鈥揅6) is higher than in water and generally decreases with a Many drugs contain an imidazole ring, such as certain antifungal drugs, the nitroimidazole series of antibiotics, and the sedative midazolam.COA of Formula: C16H21Cl2N3O2

Referemce:
Imidazole – Wikipedia,
Imidazole | C3H4N2 – PubChem

Prognostic impact of rapid reduction of involved free light chains in multiple myeloma patients under first-line treatment with Bendamustine, Prednisone, and Bortezomib (BPV) was written by Holzhey, Tanja;Poenisch, Wolfram;Wang, Song-Yau;Holzvogt, Madlen;Holzvogt, Bruno;Andrea, Marc;Zehrfeld, Thomas;Hammerschmidt, Doreen;Hoffmann, Franz Albert;Becker, Cornelia;Schwarzer, Andreas;Schwarz, Maik;Schoenfelder-Fricke, Uta;Edelmann, Thomas;Braunert, Leanthe;Franke, Georg-Nikolaus;Jentzsch, Madlen;Schwind, Sebastian;Bill, Markus;Grimm, Juliane;Remane, Yvonne;Platzbecker, Uwe;Scholz, Markus. And the article was included in Journal of Cancer Research and Clinical Oncology in 2021.Electric Literature of C16H21Cl2N3O2 The following contents are mentioned in the article:

Light chain involvement is observed in almost every patient (pt) with newly diagnosed multiple myeloma (MM). Owing to a relatively short half-life, rapid reduction in the involved free light chain (iFLC) is of potential prognostic value. This retrospective anal. included 92 pts with newly diagnosed MM treated with bendamustine, prednisone, and bortezomib (BPV). After a median number of two (range 1-5) BPV cycles, the majority of pts (n = 86; 93%) responded with either sCR (n = 21), CR (n = 1), nCR (n = 25), VGPR (n = 20), or PR (n = 19). PFS and OS at 48 mo were 39% and 67%, resp. At baseline, 79 out of 92 pts (86%) had iFLC levels above the upper standard level and an abnormal ratio of involved to uninvolved free light chain 鈮?8. In a subgroup anal. of these pts, we evaluated the prognostic importance of an early reduction of the iFLC during the first two BPV cycles. A reduction 鈮?50% of the iFLC on day 8 of the first cycle was observed in 31 of 69 pts. These pts had a significantly better median PFS of 49 mo as compared to 20 mo in 38 pts with a lower iFLC reduction (p = 0.002). In contrast, OS did not differ significantly with a 48 mo survival of 77% vs 69% (p > 0.05). These results indicate that a rapid decrease in the iFLC on day 8 is an early prognostic marker for newly diagnosed MM pts undergoing BPV treatment. This study involved multiple reactions and reactants, such as 4-(5-(Bis(2-chloroethyl)amino)-1-methyl-1H-benzo[d]imidazol-2-yl)butanoic acid (cas: 16506-27-7Electric Literature of C16H21Cl2N3O2).

4-(5-(Bis(2-chloroethyl)amino)-1-methyl-1H-benzo[d]imidazol-2-yl)butanoic acid (cas: 16506-27-7) belongs to imidazole derivatives. Imidazole is the basic core of some natural products such as histidine, purine, histamine and DNA based structures, etc. Among the different heterocyclic compounds, imidazole is better known due to its broad range of chemical and biological properties. This ring system is present in important biological building blocks, such as histidine and the related hormone histamine.Electric Literature of C16H21Cl2N3O2

Referemce:
Imidazole – Wikipedia,
Imidazole | C3H4N2 – PubChem

Zanubrutinib for treatment-naive and relapsed/refractory chronic lymphocytic leukaemia: long-term follow-up of the phase I/II AU-003 study was written by Cull, Gavin;Burger, Jan A.;Opat, Stephen;Gottlieb, David;Verner, Emma;Trotman, Judith;Marlton, Paula;Munoz, Javier;Johnston, Patrick;Simpson, David;Stern, Jennifer C.;Prathikanti, Radha;Wu, Kenneth;Novotny, William;Huang, Jane;Tam, Constantine S.. And the article was included in British Journal of Haematology in 2022.Product Details of 16506-27-7 The following contents are mentioned in the article:

Summary : The phase I/II AU-003 study in patients with treatment-naive (TN) or relapsed/refractory (R/R) chronic lymphocytic leukemia/small lymphocytic lymphoma demonstrated that zanubrutinib therapy results in clin. meaningful and durable responses with acceptable safety and tolerability. We report updated safety and efficacy data for 123 patients with a median follow-up of 47路2 mo. Patients received zanubrutinib 160 mg twice daily (81 patients), 320 mg once daily (40), or 160 mg once daily (two). Discontinuations due to adverse events or disease progression were uncommon. The overall response rate (ORR) was 95路9% (TN, 100%; R/R, 95%) with 18路7% achieving complete response (CR). Ongoing response at 3 years was reported in 85路7%. The ORR in patients with del(17p)/tumor protein p53 mutation was 87路5% (CR 16路7%). The 2- and 3-yr progression-free survival estimates were 90% (TN, 90%; R/R, 91%) and 83% (TN, 81%; R/R, 83%) resp. The most reported Grade 鈮? adverse events were neutropenia (15路4%), pneumonia (9路8%), hypertension (8路9%) and anemia (6路5%). The annual incidence of atrial fibrillation, major hemorrhage, Grade 鈮? neutropenia and Grade 鈮? infection decreased over time. With a median follow-up of 鈭? years, responses remain clin. meaningful and durable and long-term tolerability to zanubrutinib therapy continues. This study involved multiple reactions and reactants, such as 4-(5-(Bis(2-chloroethyl)amino)-1-methyl-1H-benzo[d]imidazol-2-yl)butanoic acid (cas: 16506-27-7Product Details of 16506-27-7).

4-(5-(Bis(2-chloroethyl)amino)-1-methyl-1H-benzo[d]imidazol-2-yl)butanoic acid (cas: 16506-27-7) belongs to imidazole derivatives. Many natural products, especially alkaloids, contain the imidazole ring. These imidazoles share the 1,3-C3N2 ring but feature varied substituents. This ring system is present in important biological building blocks, such as histidine and the related hormone histamine.Product Details of 16506-27-7

Referemce:
Imidazole – Wikipedia,
Imidazole | C3H4N2 – PubChem

Impact of rituximab on COVID-19 outcomes was written by Levavi, Hannah;Lancman, Guido;Gabrilove, Janice. And the article was included in Annals of Hematology in 2021.Reference of 16506-27-7 The following contents are mentioned in the article:

Rituximab is associated with prolonged B-cell depletion and secondary hypogammaglobulinemia and is associated with a dampened humoral response and increased infectious complications. To describe the potential impact of prior rituximab therapy on clin. outcomes from SARS-CoV-2 infection and development of COVID-19 antibodies, we conducted a retrospective study of adults across the Mount Sinai Health System diagnosed with COVID-19 who received rituximab for any indication from Feb. 2019 to Oct. 2020. Patients’ baseline characteristics, markers of disease severity, clin. outcomes, and antibody development were examined Of the 49 patients included in the anal., 63.2% required hospitalization for COVID-19, 24.5% required an ICU admission, and 32.7% died. Proximity of last rituximab infusion and COVID-19 diagnosis did not affect rates of hospitalization, admission to intensive care units or death. Over half (51.7%) of those whose antibodies were checked developed neutralizing anti-spike protein antibodies. The median time between rituximab administration and COVID-19 diagnosis was not significantly different between those who developed antibodies and those who did not (p = .323). Of the 14 patients with documented neg. COVID-19 antibody titers, 11 of them survived SARS-CoV-2 infection, indicating that development of neutralizing antibodies may not be necessary for recovery from COVID-19. This study involved multiple reactions and reactants, such as 4-(5-(Bis(2-chloroethyl)amino)-1-methyl-1H-benzo[d]imidazol-2-yl)butanoic acid (cas: 16506-27-7Reference of 16506-27-7).

4-(5-(Bis(2-chloroethyl)amino)-1-methyl-1H-benzo[d]imidazol-2-yl)butanoic acid (cas: 16506-27-7) belongs to imidazole derivatives. Many natural products, especially alkaloids, contain the imidazole ring. These imidazoles share the 1,3-C3N2 ring but feature varied substituents. The pharmacophore of imidazole exists in bioactive compounds including amino acids, plant growth regulators and therapeutic agents.n increase of the alkyl chain length of the alcohols. Reference of 16506-27-7

Referemce:
Imidazole – Wikipedia,
Imidazole | C3H4N2 – PubChem

Viral Evolution and Immunology of SARS-CoV-2 in a Persistent Infection after Treatment with Rituximab was written by Van der Moeren, Nathalie;Selhorst, Philippe;Ha, My;Heireman, Laura;Van Gaal, Pieter-Jan;Breems, Dimitri;Meysman, Pieter;Laukens, Kris;Verstrepen, Walter;Van Gasse, Natasja;Ogunjimi, Benson;Arien, Kevin K.;Naesens, Reinout. And the article was included in Viruses in 2022.Formula: C16H21Cl2N3O2 The following contents are mentioned in the article:

Prolonged shedding of SARS-CoV-2 in immunocompromised patients has been described. Furthermore, an accumulation of mutations of the SARS-CoV-2 genome in these patients has been observed We describe the viral evolution, immunol. response and clin. course of a patient with a lymphoma in complete remission who had received therapy with rituximab and remained SARS-CoV-2 RT-qPCR pos. for 161 days. The patient remained hospitalised for 10 days, after which he fully recovered and remained asymptomatic. A progressive increase in Ct-value, coinciding with a progressive rise in lymphocyte count, was seen from day 137 onward. Culture of a nasopharyngeal swab on day 67 showed growth of SARS-CoV-2. Whole genome sequencing (WGS) demonstrated that the virus belonged to the wildtype SARS-CoV-2 clade 20B/GR, but rapidly accumulated a high number of mutations as well as deletions in the N-terminal domain of its spike protein. SARS-CoV-2 persistence in immunocompromised individuals has important clin. implications, but halting immunosuppressive therapy might result in a favorable clin. course. The long-term shedding of viable virus necessitates customized infection prevention measures in these individuals. The observed accelerated accumulation of mutations of the SARS-CoV-2 genome in these patients might facilitate the origin of new VOCs that might subsequently spread in the general community. This study involved multiple reactions and reactants, such as 4-(5-(Bis(2-chloroethyl)amino)-1-methyl-1H-benzo[d]imidazol-2-yl)butanoic acid (cas: 16506-27-7Formula: C16H21Cl2N3O2).

4-(5-(Bis(2-chloroethyl)amino)-1-methyl-1H-benzo[d]imidazol-2-yl)butanoic acid (cas: 16506-27-7) belongs to imidazole derivatives. 1H-imidazole is an imidazole tautomer which has the migrating hydrogen at position 1. It is a conjugate base of an imidazolium cation. It is a conjugate acid of an imidazolide. It is a tautomer of a 4H-imidazole. The pharmacophore of imidazole exists in bioactive compounds including amino acids, plant growth regulators and therapeutic agents.n increase of the alkyl chain length of the alcohols. Formula: C16H21Cl2N3O2

Referemce:
Imidazole – Wikipedia,
Imidazole | C3H4N2 – PubChem